Clinical trial
Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma
NCT00143871 · University of Michigan Rogel Cancer Center, Other · Completed
Key facts
| NCT number | NCT00143871 |
|---|---|
| Title | Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma |
| Official title | Rituximab Plus High-dose Chemotherapy With Autologous Stem Cell Support for Non-Hodgkin's Lymphoma |
| Lead sponsor | University of Michigan Rogel Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Non-Hodgkin's |
| Intervention type | Drug |
| Interventions | Rituximab |
| Enrollment | 35 |
| Start date | Apr 1, 2001 |
| Primary completion | Dec 1, 2006 |
| Completion | Jan 1, 2007 |
| First posted | Sep 2, 2005 |
| Last update posted | Feb 1, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: